Given the rapid recovery observed in most patients infected with recent SARS-CoV-2 variants by day 6, the detection timeline of the IBMP ELISA IgA/IgM/IgG COVID-19, which identifies seroconversion at 6 days post onset (in contrast to the GOLD ELISA COVID-19 IgG/IgM at 4–5 days), may not be sufficiently prompt to inform treatment strategies in acute cases. The gene discussed is CD79A; the disease is COVID-19.